The company’s stock rose in its first two days on public markets, closing on Monday up almost 58% over the IPO price amid ...

HeartFlow’s current products are HeartFlow Plaque analysis, which aims to provide clinicians with the ability to more ...

Heartflow has priced its previously announced initial public offering (IPO), with proceeds potentially reaching up to $300 ...

Backed by Bain Capital, the health technology startup makes 3D models of people's hearts to help diagnose diseases. Here's ...

Heartflow, backed by private investment firm Bain Capital, said on Wednesday it was targeting a valuation of up to $1.46 ...

Heartflow (NASDAQ: HTFL) stock surges ~50% as the company focused on AI-driven tools for the diagnosis of heart diseases make ...

The Bain Capital-backed company's debut comes as expectations of a softer trade policy and lower interest rates boost ...

Heartflow announced today that it closed its upsized initial public offering (IPO) with proceeds totaling approximately $364.2 million.

Heartflow (HTFL) on Thursday announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of $19.00 per share.

Heartflow, a company involved in AI technology for coronary artery disease, went public on Friday under the ticker symbol HTFL, raising $316.7 million with its initial public offering. Late last week, ...

Medical technology firm Heartflow said on Thursday it had raised $316.7 million in its U.S. initial public offering, setting the stage for its Nasdaq debut in another test of investor appetite for ...

Heartflow has pumped up its IPO ambitions, raising its proposal into the vicinity of $300 million. | After first pricing its offering earlier this month, the AI-powered coronary diagnostic developer ...